Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: Implications for antipsychotic drug treatment

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 1145-1151

  Tarazi, Frank I ^a,b,c   Baldessarini, Ross J ^a,b   Kula, Nora S ^a,b   Zhang, Kehong ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; HIPPOCAMPUS; ISOTOPE LABELING; MOLECULAR INTERACTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RAT; SECOND MESSENGER;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; MALE; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE;

EID: 0041430707     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.052597     Document Type: Article

References (51)

1. Aghajanian GK and Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31:302-312.
2. Ariano MA, Larson ER, Noblett KL, Sibley DR, and Levine MS (1997) Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. Synapse 26:400-414.
3. Arnt J and Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
4. Baldessarini RJ and Tarazi FI (2001) Drugs and the treatment of psychiatric disorders, in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, and Gilman AG, eds) pp 485-520, McGraw-Hill Companies, New York.
5. Boegman RJ and Vincent SR (1996) Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse 22:70-77.
6. 2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons. J Biol Chem 277:36553-36562.
7. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, and Carlsson ML (2001) Interactions between monoamines, glutamate and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260.
8. Carta M, Olivera DS, Dettmer TS, and Valenzuela CF (2002) Ethanol withdrawal up-regulates kainate receptors in cultured rat hippocampal neurons. Neurosci Lett 327:128-132.
9. Cepeda C, Buchwald NA, and Levine MS (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 90:9576-9580.
10. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
11. Ellenbroek BA, Lubbers LJ, and Cools AR (1996) Activity of Seroquel (ICI-204,636) in animal models for atypical properties of antipsychotics, comparison with clozapine. Neuropsychopharmacology 15:406-416.
12. Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, and Nestler EJ (1995) Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 15:2453-2461.
13. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, and Tamminga CA (2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157:1141-11499.
14. 3H]kainate binding in hippocampus 24 hours after PCP. Neurosci Lett 174:149-153.
15. 3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas. Brain Res 762:216-218.
16. Goff DC and Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377.
17. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, and Lynch G (2001) A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21:484-487.
18. Hall RA, Massicotte G, Kessler M, Baudry M, and Lynch G (1993) Thiocyanate equally increases affinity for two DL-alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA) receptor states. Mol Pharmacol 43:459-464.
19. Healy DJ and Meador-Woodruff JH (1997) Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Mol Brain Res 47:331-338.
20. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science (Wash DC) 252:851-853.
21. Hollmann M and Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31-108.
22. Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
23. Krieckhaus EE, Donahoe JW, and Morgan MA (1992) Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry 31:560-570.
24. Lerma J (1998) Kainate receptors: an interplay between excitatory and inhibitory synapses. FEBS Lett 430:100-104.
25. Lidsky TI, Yablonsky-Alter E, Zuck L, and Banerjee SP (1993) Anti-glutamatergic effects of clozapine. Neurosci Lett 163:155-158.
26. McCoy L, Cox C, and Richfield EK (1996) Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. Eur J Pharmacol 318:41-45.
27. McCoy L, Cox C, and Richfield EK (1998) Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse 28:195-207.
28. Meador-Woodruff JH and Healy DJ (2000) Glutamate receptor expression in schizophrenic brain. Brain Res Rev 31:288-294.
29. Meshul CK, Bunker GL, Mason JN, Allen C, and Janowsky A (1996) Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J Neurochem 67:1965-1973.
30. Moore NA, Tye NC, Axton MS, and Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 270:713-721.
31. Miller MW (1988) Development of projection and local circuit neurons in neocortex, in Cerebral Cortex, Development and Maturation of Cerebral Cortex (Peters A and Jones EG eds) pp 133-175, Plenum Press, New York.
32. 3H]alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid binding sites. J Neurochem 54:686-695.
33. Ozawa S, Kamiya H, and Tsuzuki K (1998) Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54:581-618.
34. Paxinos F and Watson C (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
35. 3H-Labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci USA 84:7744-7748.
36. Riva MA, Tascedda F, Lovati E, and Racagni G (1997) Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Mol Brain Res 50:136-142.
37. Schmidt WJ and Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621-623.
38. Short KR and Tabakoff B (1993) Chronic barbiturate treatment increases NMDA receptors but decreases kainate receptors in mouse cortex. Eur J Pharmacol 230:111-114.
39. Spurney CF, Baca SM, Murray AM, Jaskiw GE, Kleinmann JE, and Hyde TM (1999) Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 34:266-276.
40. Tarazi FI, Campbell A, Yeghiayan SK, and Baldessarini RJ (1998) Localization of glutamate receptor subtypes in caudate-putamen and nucleus accumbens septi: comparison of NMDA, AMPA and kainate receptors. Synapse 30:227-235.
41. Tarazi FI, Florijn WJ, and Creese I (1996) Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 128:371-379.
42. Tarazi FI, Zhang K, and Baldessarini RJ (2000) Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. Brain Res 881:69-72.
43. Tarazi FI, Zhang K, and Baldessarini RJ (2001) Long-term effects of olanzapine, risperidone and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 297:711-717.
44. Tarazi FI, Zhang K, and Baldessarini RJ (2002) Long-term effects of olanzapine, risperidone and quetiapine on serotonin receptors 1A, 2A and 2C in rat forebrain. Psychopharmacology 161:263-270.
45. Tarsy D, Baldessarini EJ, and Tarazi FI (2002) Atypical antipsychotic agents: effects on extrapyramidal function. CNS Drugs 16:23-45.
46. Taseedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A, Bravi D, Carra S, Racagni G, and Riva MA (2001) Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50:117-122.
47. Tascedda F, Lovati E, Blom JM, Muzzioli P, Brunello N, Racagni G, and Riva MA (1999) Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 21:211-217.
48. Tsai G and Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179.
49. Yoshida Y, Ono T, Kizu A, Fukushima R, and Miyagishi T (1991) Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. Eur J Pharmacol 203:173-180.
50. Waddington JL and Casey D (2000) Comparative pharmacology of classical and novel (second-generation) antipsychotics, in Schizophrenia and Mood Disorders (Waddington JL and Buckley PF eds) pp 1-13, Butterworth-Heinemann, Oxford.
51. Wullner U, Testa CM, Catania MV, Young AB, and Penney JB (1994) Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res 645:98-102.